Hirsutism and hypertrichosis

Hair and Scalp Diseases: Medical, Surgical, and Cosmetic Treatments

Volumn , Issue , 2008, Pages 211-224

  Kerchner, Katherine R ^a   McMichael, Amy J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 56649116566     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (56)

1. Sonino N, Fava GA, Mani, E, et al. Quality of life of hirsute women. Postgrad Med J 1993; 69:186-189.
2. Rosenfield RL. Hirsuitism. N Engl J Med 2005; 353:2578-2588.
3. Hock DL, Seifer DB. New treatments of hyperandrogenism and hirsutism. Obstet Gynecol Clin North Am 2000; 27:567-581.
4. Ploufe L. Disorders of excessive hair growth in adolescent. Obstet Gynecol Clin North Am 2000; 27:79-99.
5. Rittmaster, RS. Hirsutism. Lancet 1997; 349:191-195.
6. Hamilton J. The hirsute female: racial and genetic predisposition. Clin Obstet Gynecol 1964; 10 1075-1084.
7. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21:1440-1447.
8. DeUgarte CM, Woods KS, Azziz R, et al. Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab 2006; 91:1345-1350.
9. Housman TS, Derrow AE, Snively BM, et al. Women with excessive facial hair: a statistical evaluation and review of impact on quality of life. Cosmetic Derm 2004; 17(3):157-165.
10. Knochenhauer ES, Key, TJ, Azziz R, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern united states: a prospective study. J Clin Endocrinol Metab 1998; 83:3078-3082.
11. Hines G, Moran C, Azziz R, et al. Facial and abdominal hair growth in hirsutism: a computerized evaluation. JAAD 2001; 45:846-850.
12. Carmina E, Koyama T, Lobo R. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 1992; 167:1807-1812.
13. Lanham MS, Lebovic DI, Domino SE. Contemporary medical therapy for polycystic ovary syndrome. Int J Gynaecol Obstet 2006; 95:236-241.
14. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41-47.
15. Carmina E. Prevalence of idiopathic hirsutism. European J of Endo 1998; 139:421-423.
16. Azziz R, Carmina E, Sawaya M. Idiopathic hirsutism. Endocr Rev 2000; 21:347-362.
17. Mestayer C, Berthaut I, Portois MC, et al. Predominant expression of 5α-reductase type 1 in pubic skin from normal subjects and hirsute patients. J Clin Endocrinol Metab 1996; 81:1989-1993.
18. Legro R, Shahbahrami B, Kovacs B, et al. Size polymorphisms of the androgen receptor among female Hispanics and correlation with androgenic characteristics. Obstet Gynecol 1994; 83:701-706.
19. Paus R. Control of the hair cycle and hair diseases as cycling disorders. Curr Opin Dermatol 1996; 3:248-258.
20. Wagner R. Physical methods for the management of hirsutism. Cutis 1990; 45:319-326.
21. Ebling FJ. Hair. J Invest Dermatol 1976; 67:98-105.
22. Lynfield YL, Macwilliams P. Shaving and hair growth. J Invest Dermatol 1970; 55:170-172.
23. Liew SH. Unwanted body hair and its removal: a review. Dermatol Surg 1999; 25:431-439.
24. Goldberg NS, Zalka AD. Retin-A and wax epilation. Arch Dermatol 1989; 125:1717.
25. Romo ME. Isotretinoin and wax epilation. Br J Dermatol 1991; 124:393.
26. Haedersdal M, Gotzsche PC. Laser and photoepilation for unwanted hair growth. Cochrane Database Syst Rev 2006; 4.
27. Lim SP, Lanigan SW. A review of the adverse effects of laser hair removal. Lasers Med Sci 2006; 21:121-125.
28. Smith SR, Piacquadio DJ, Littler C, et al. Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial. Dermatol Surg 2006; 32:1237-1243.
29. Wolf JE, Shander D, Schrode K, et al. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. Int J of Dermatol 2007; 46:94-98.
30. Kokaly W, McKenna TJ. Relapse of hirsutism following long-term successful treatment with oestrogen-progestogen combination. Clin Endocrinol 2000; 52:379-382.
31. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol 2003; 101:995-1007.
32. Moghetti P, Toscano V. Treatment of hirsutism and acne in hyperandrogenism. Best Pract Res Clin Endocrinol Metab 2006; 20:221-234.
33. Derman R. Androgen excess in women. Int J Fertil 1996; 41:172-176.
34. Heiner JS, Greendale GA, Judd HL, et al. Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism. J Clin Endocrinol Metab 1995; 80:3412-3418.
35. Dahlgren E, Landin K, Janson PO. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reproduct 13:2706-2711.
36. Carmina E, Lobo RA. The addition of dexamethasone to antiandrogen therapy for hirsutism prolongs the duration of remission. Fertil Steril 1998; 69:1075-1079.
37. Farquhar C, Lee O, Jepson R. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev 2003; 4:CD000194.
38. Marcondes JA, Minnani SL, Kirschner MA, et al. Treatment of hirsutism in women with flutamide. Fertil Steril 1992; 57:543-547.
39. Motta T, Maggi G, D'Alberton A, et al. Flutamide in the treatment of hirsutism. Int J Gynecol Obstet 1991; 36:155-157.
40. Cusan L, Dupont A, Labrie F, et al. Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol 1990; 23:462-469.
41. Cusan L, Dupont A, Labrie F, et al. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril 1994; 61:281-287.
42. Moghetti P, Tosi F, Castello R, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2000; 85:89-94.
43. Venturoli S, Marescalchi O, Flamigni C, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999; 84:1304-1310.
44. Fruzzetti F, Bersi C, Genazzani AR, et al. Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects. Fertil Steril 1999; 71:445-451.
45. Kelestimur F, Everest H, Sahin Y, et al. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Eur J Endocrinol 2004; 150:351-354.
46. Morin-Papunen LC, Koivunen RM, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998; 69:691-696.
47. Wendelin, DS, Pope DN, Mallory SB. Hypertrichosis. J Am Acad Dermatol 2003; 48:161-179.
48. Vashi RA, Mancini AJ, Paller AS. Primary generalized and localized hypertrichosis in children. Arch Dermatol 2001; 137:877-884.
49. Krause K, Foitzik K. Biology of the hair follicle: The basics. Semin Cutan Med Surg 2006; 25:2-10.
50. Jankovic SM, Jankovic SV. The control of hair growth. Dermatol Online J 1998; 4:2.
51. Bondeson J, Miles AE. The hairy family of Burma: a four generation pedigree of congenital hypertrichosis lanuginose. J R Soc Med 1996; 89:403-408.
52. James W, Berger T, Elston D. Diseases of the skin appendages: hypertrichosis. In: Andrews' Diseases of the Skin: Clinical Dermatology. 10th ed. Philadelphia: Elsevier, 2006:769-771.
53. Trueb RM. Causes and management of hypertrichosis. Am J Clin Dermatol 2002; 3:617-627.
54. Camacho-Martinez, F. Hypertrichosis and hirsutism. In: Bolognia J, Jorizzo J, Rapini R, eds. Dermatology. 1st ed. Edinburgh: Mosby, 2003:1051-1053.
55. Tay YK, Bellus G, Weston W. What syndrome is this? Gingival Fibromatosis-hypertrichosis syndrome. Pediatr Dermatol 2001; 18:534-536.
56. Wyatt JP, Anderson HF, Cordoro KM, et al. Acquired hypertrichosis lanuginosa as a presenting sign of metastatic prostate cancer with rapid resolution after treatment. J Am Acad Dermatol 2007; 56: S45-S47.